

CITATION REPORT

List of articles citing

**MGMT promoter methylation in malignant gliomas:
ready for personalized medicine?**

DOI: 10.1038/nrneurol.2009.197

Nature Reviews Neurology, 2010, 6, 39-51.

Source: <https://exaly.com/paper-pdf/47801666/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
592	Clinical application of the blink reflex with stimulation of the mental nerve in lesions of the inferior alveolar nerve. 1994 , 44, 2356-61		25
591	Glioma diagnosis: immunohistochemistry and beyond. 2010 , 17, 187-201		46
590	Demethylating Agents in the Treatment of Cancer. 2010 , 3, 2022-2044		41
589	Targeting DNA repair proteins for cancer treatment. 2010 , 67, 3569-72		21
588	Targeting O ⁶ methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. 2010 , 67, 3663-81		103
587	[Anaplastic glioma. Neuropathology, molecular diagnostics and current study concepts]. 2010 , 81, 928-30, 932-5		1
586	Molecular diagnostics of gliomas: state of the art. 2010 , 120, 567-84		208
585	Molecular diagnostics of gliomas: the clinical perspective. 2010 , 120, 585-92		96
584	Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. 2010 , 120, 707-18		596
583	MGMT promoter methylation in malignant gliomas. 2010 , 5, 161-5		52
582	Newly diagnosed high-grade gliomas. 2010 , 12, 309-20		5
581	MGMT promoter methylation status in anaplastic meningiomas. <i>Journal of Neuro-Oncology</i> , 2010 , 100, 489-90	4.8	12
580	American Association for Cancer Research Genetics and Biology of Brain Cancers 2009, December 13-15, 2009, San Diego, CA. <i>Journal of Neuro-Oncology</i> , 2010 , 99, 297-306	4.8	2
579	Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. 2010 , 9, 717-26		216
578	MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. 2010 , 127, 2106-18		80
577	Epigenetic modifications as therapeutic targets. 2010 , 28, 1069-78		580
576	Gliomas in adults. 2010 , 107, 799-807; quiz 808		42

575	Comparison of Different Promoter Methylation Assays in Breast Cancer. 2010 , 33, 133-141	25
574	The future role of personalized medicine in the treatment of glioblastoma multiforme. 2010 , 3, 111-27	12
573	Temozolomide and MGMT forever?. <i>Neuro-Oncology</i> , 2010 , 12, 219-20	1 5
572	A cross-disciplinary approach to understanding neural stem cells in development and disease. 2010 , 137, 1933-8	3
571	Therapy for recurrent high-grade gliomas: does continuous dose-intense temozolomide have a role?. 2010 , 28, 1977-9	10
570	BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. 2010 , 28, e563-4; author reply e565-6	129
569	Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. 2010 , 28, 2712-8	338
568	Overview of cellular immunotherapy for patients with glioblastoma. 2010 , 2010,	62
567	Frequent MGMT (O(6)-methylguanine-DNA methyltransferase) hypermethylation in long-term survivors of glioblastoma: a single institution experience. 2010 , 44, 113-20	11
566	Neues in der Neuroonkologie. 2010 , 37, 388-393	
565	Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?. 2010 , 6, 1407-14	20
564	Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. 2010 , 9, 135	203
563	High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2010 , 21 Suppl 5, v190-3	212
562	DNA methylation and cancer. 2010 , 70, 27-56	861
561	Neuro-oncology, a decade of temozolomide and beyond. 2010 , 10, 1675-7	15
560	The pathological diagnosis of diffuse gliomas: towards a smart synthesis of microscopic and molecular information in a multidisciplinary context. 2011 , 17, 486-494	41
559	Multifaceted roles of alkyltransferase and related proteins in DNA repair, DNA damage, resistance to chemotherapy, and research tools. 2011 , 24, 618-39	144
558	Molecular targeting of glioblastoma: Drug discovery and therapies. 2011 , 17, 301-312	99

557	Co-occurrence of MGMT gene promoter methylation and amplification of EGFR in glioblastoma. 2011 , 6, 362-366		1
556	Metabolism and brain cancer. 2011 , 66 Suppl 1, 33-43		75
555	[MGMT analysis in gliomas]. 2011 , 98, 291-303		2
554	Personalized medicine in oncology: vision or realistic concept?. 2011 , 1, 1-6		
553	Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM. 2011 , 6, e16146		65
552	Treating the neurosurgical patient: beyond the pathology and technology. 2011 , 38, 1-2		1
551	Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma. 2011 , 66, 1747-55		62
550	NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. 2011 , 9 Suppl 5, S1-32; quiz S33		195
549	Cancer epigenetics reaches mainstream oncology. 2011 , 17, 330-9		920
548	Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis. 2011 , 30, 978-89		46
547	Molecular diagnostics in neuro-oncology. Introduction. 2011 , 21, 55-6		
546	Unraveling the glioma epigenome: from molecular mechanisms to novel biomarkers and therapeutic targets. 2011 , 21, 619-32		33
545	Recurrent glioblastoma: a fresh look at current therapies and emerging novel approaches. 2011 , 38 Suppl 4, S21-33		38
544	O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry. 2011 , 1816, 179-90		99
543	Determination of the methylation status of MGMT in different regions within glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2011 , 102, 255-60	4.8	42
542	Primer extension based quantitative polymerase chain reaction reveals consistent differences in the methylation status of the MGMT promoter in diffusely infiltrating gliomas (WHO grade II-IV) of adults. <i>Journal of Neuro-Oncology</i> , 2011 , 104, 293-303	4.8	16
541	O6-methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastoma. 2011 , 28, 127-35		26
540	Aktuelle Prinzipien der Behandlung maligner Gliome. 2011 , 17, 255-263		

539	Prognostic impact of hemoglobin level and other factors in patients with high-grade gliomas treated with postoperative radiochemotherapy and sequential chemotherapy based on temozolomide: a 10-year experience at a single institution. 2011 , 187, 778-83		8
538	Genomic profiles of glioma. 2011 , 11, 291-7		34
537	O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction. 2011 , 11, 35		34
536	Systematic cross-validation of 454 sequencing and pyrosequencing for the exact quantification of DNA methylation patterns with single CpG resolution. 2011 , 11, 6		35
535	Sensitivity to cisplatin in primary cell lines derived from human glioma correlates with levels of EGR-1 expression. 2011 , 11, 5		9
534	Overexpression of the orphan receptor Nur77 and its translocation induced by PCH4 may inhibit malignant glioma cell growth and induce cell apoptosis. 2011 , 103, 442-50		32
533	Current concepts and management of glioblastoma. 2011 , 70, 9-21		319
532	Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. 2011 , 129, 659-70		213
531	Molecular markers in low-grade gliomas: predictive or prognostic?. 2011 , 17, 4588-99		145
530	Methylation markers in the clinical management of leukemia patients: wave of the future or just damp squib?. 2011 , 3, 391-4		
529	DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression. <i>Neuro-Oncology</i> , 2011 , 13, 280-9	1	54
528	Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. <i>Neuro-Oncology</i> , 2011 , 13, 307-16	1	187
527	The A/G allele of rs16906252 predicts for MGMT methylation and is selectively silenced in premalignant lesions from smokers and in lung adenocarcinomas. 2011 , 17, 2014-23		42
526	Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients. <i>Neuro-Oncology</i> , 2011 , 13, 195-202	1	47
525	Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres. 2011 , 17, 255-66		67
524	DNA methylation in personalized medicine. 2011 , 8, 35-43		4
523	The role of integrins in glioma biology and anti-glioma therapies. 2011 , 17, 2402-10		33
522	Recurrent high-grade glioma: a diagnostic and therapeutic challenge. 2011 , 11, 509-18		19

521	The correlation between promoter methylation status and the expression level of O6-methylguanine-DNA methyltransferase in recurrent glioma. 2011 , 41, 190-6		10
520	Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. <i>Neuro-Oncology</i> , 2011 , 13, 317-23	1	233
519	Combining stereotactic radiosurgery and systemic therapy for brain metastases: a potential role for temozolomide. <i>Frontiers in Oncology</i> , 2012 , 2, 99	5.3	3
518	Gliosis versus glioma?: don't grade until you know. 2012 , 19, 239-49		34
517	Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. <i>Neuro-Oncology</i> , 2012 , 14 Suppl 4, iv100-8	1	120
516	Moving toward molecular classification of diffuse gliomas in adults. 2012 , 79, 1917-26		54
515	Fluorescence guidance during stereotactic biopsy. 2012 ,		1
514	Glioma and Other Neuroepithelial Neoplasms. 2012 , 767-794		
513	DNA methylation biomarkers and their utility for solid cancer diagnostics. 2012 , 50, 1707-21		59
512	MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry. 2012 , 138, 1789-97		18
511	Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. 2012 , 61, 2033-44		106
510	The DNA damage response and cancer therapy. 2012 , 481, 287-94		1118
509	Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. 2012 , 13, 707-15		792
508	The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2012 , 110, 325-33	4.8	60
507	Irradiation and bevacizumab in high-grade glioma retreatment settings. 2012 , 82, 67-76		109
506	Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas. 2012 , 82, 749-55		60
505	Nimotuzumab treatment of malignant gliomas. 2012 , 12, 1649-59		44
504	O6-Methylguanine-DNA methyltransferase is a novel negative effector of invasion in glioblastoma multiforme. 2012 , 11, 2440-50		15

503	Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. 2012 , 122, 444-55	107
502	Molecular mechanisms of temozolomide resistance in glioblastoma multiforme. 2012 , 12, 635-42	88
501	Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. 2012 , 15, 21-38	192
500	Folate supplementation limits the tumourigenesis in rodent models of gliomagenesis. 2012 , 48, 2431-41	17
499	Glioblastoma research 2006-2010: pattern of citation and systematic review of highly cited articles. 2012 , 114, 1207-10	12
498	MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. 2012 , 124, 547-60	213
497	Tumor-derived hepatocyte growth factor is associated with poor prognosis of patients with glioma and influences the chemosensitivity of glioma cell line to cisplatin in vitro. 2012 , 10, 128	8
496	MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy. 2012 , 10, 250	58
495	Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. 2012 , 7, e30339	99
494	Identification, validation and clinical implementation of cancer biomarkers: Translational strategies of the EORTC PathoBiology Group. 2012 , 10, 120-127	3
493	Epilepsy meets cancer: when, why, and what to do about it?. 2012 , 13, e375-82	107
492	Clinical neuropathology practice guide 06-2012: MGMT testing in elderly glioblastoma patients--yes, but how?. 2012 , 31, 405-8	19
491	Biomarkers classification and therapeutic decision-making for malignant gliomas. 2012 , 13, 417-36	22
490	Downregulation of PRDX1 by promoter hypermethylation is frequent in 1p/19q-deleted oligodendroglial tumours and increases radio- and chemosensitivity of Hs683 glioma cells in vitro. 2012 , 31, 3409-18	32
489	O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is a rare event in soft tissue sarcoma. 2012 , 7, 180	4
488	Post-transcriptional regulation of O(6)-methylguanine-DNA methyltransferase MGMT in glioblastomas. 2011 , 10, 185-93	28
487	Quantitative, high-resolution CpG methylation assays on the pyrosequencingplatform. 223-234	
486	Promoter CpG island methylation in colorectal cancer:. 306-322	

485	Molecular biomarkers of glioblastoma: current targets and clinical implications. 2012 , 63	4
484	Volumetric and MGMT parameters in glioblastoma patients: survival analysis. 2012 , 12, 3	51
483	Knockdown of stomatin-like protein 2 (STOML2) reduces the invasive ability of glioma cells through inhibition of the NF- κ B/MMP-9 pathway. 2012 , 226, 534-43	27
482	MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations. 2012 , 131, 1104-13	55
481	Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. 2012 , 131, 1342-50	180
480	Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts. 2012 , 18, 4070-9	92
479	Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltransferase in a series of 100 glioblastoma patients. 2012 , 118, 4201-11	149
478	Clinical implications of molecular neuropathology and biomarkers for malignant glioma. 2012 , 12, 302-7	20
477	Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging. 2012 , 54, 555-63	85
476	O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems. 2012 , 1826, 71-82	59
475	Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies. 2012 , 39, 109-22	39
474	Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. 2012 , 38, 271-91	86
473	Expression of O6-methylguanine DNA methyltransferase (MGMT) and immunohistochemical analysis of 12 pineal parenchymal tumors. 2012 , 32, 647-53	9
472	MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. 2012 , 10, 36	70
471	The hypermethylation of the O6-methylguanine-DNA methyltransferase gene promoter in gliomas--correlation with array comparative genome hybridization results and IDH1 mutation. 2012 , 51, 20-9	12
470	MGMT expression and promoter methylation status may depend on the site of surgical sample collection within glioblastoma: a possible pitfall in stratification of patients?. <i>Journal of Neuro-Oncology</i> , 2012 , 106, 33-41	4.8 27
469	Quantitative methylation analysis of HOXA3, 7, 9, and 10 genes in glioma: association with tumor WHO grade and clinical outcome. 2012 , 138, 35-47	30
468	Impact of genetic targets on cancer therapy. Forward. 2013 , 779, v-vi	1

467	A long non-coding RNA signature in glioblastoma multiforme predicts survival. 2013 , 58, 123-31		165
466	Effect of temozolomide on male gametes: an epigenetic risk to the offspring?. 2013 , 30, 827-33		15
465	Molecular neuro-oncology in clinical practice: a new horizon. 2013 , 14, e370-9		149
464	The treatment of glioblastomas: a systematic update on clinical Phase III trials. 2013 , 87, 265-82		25
463	Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy. 2013 , 110, E1480-9		24
462	The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells. <i>Neuro-Oncology</i> , 2013 , 15, 269-78	1	67
461	Update in the treatment of high-grade Gliomas. 2013 , 31, 847-67		8
460	Optimal management of elderly patients with glioblastoma. 2013 , 39, 350-7		108
459	Environmental Epigenomics in Health and Disease. <i>Epigenetics and Human Health</i> , 2013 ,		2
458	DNA methyltransferases, DNA damage repair, and cancer. 2013 , 754, 3-29		279
457	Omics and drug response. 2013 , 53, 475-502		112
456	Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status. 2013 , 23, 513-20		67
455	The role of MGMT testing in clinical practice: a report of the association for molecular pathology. 2013 , 15, 539-55		45
454	Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. 2013 , 81, 1515-22		160
453	Patterns of care and outcomes in elderly patients with glioblastoma in Sao Paulo, Brazil: a retrospective study. 2013 , 4, 388-93		6
452	Surgical resection of malignant gliomas-role in optimizing patient outcome. <i>Nature Reviews Neurology</i> , 2013 , 9, 141-51	15	106
451	Impact of genetic targets on primary brain tumor therapy: what's ready for prime time?. 2013 , 779, 267-89		11
450	Classification of Gliomas. 2013 , 3-20		

449	Assessing the MGMT status in glioblastoma: one step forward, two steps back?. <i>Neuro-Oncology</i> , 2013 , 15, 253-4	1	9
448	Epigenetics and Brain Cancer. 2013 , 21-40		
447	MicroRNA biomarkers in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2013 , 114, 13-23	4.8	45
446	Personalized medicine in neurosurgery. 2013 , 62 Suppl 1, S45-8		13
445	Optimizing glioblastoma temozolomide chemotherapy employing lentiviral-based anti-MGMT shRNA technology. 2013 , 21, 570-9		25
444	Genome-wide DNA methylation profiling identifies ALDH1A3 promoter methylation as a prognostic predictor in G-CIMP- primary glioblastoma. 2013 , 328, 120-5		53
443	Moderne Therapiestrategien bei hirneigenen glialen Tumoren. 2013 , 15, 38-51		1
442	Tumour heterogeneity in the clinic. 2013 , 501, 355-64		770
441	Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. <i>Neuro-Oncology</i> , 2013 , 15, 1405-12	1	45
440	MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. 2013 , 19, 5513-22		89
439	Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. <i>Neuro-Oncology</i> , 2013 , 15, 370-81	1	81
438	Toward a Molecular Classification of Colorectal Cancer: The Role of MGMT. <i>Frontiers in Oncology</i> , 2013 , 3, 266	5.3	15
437	Malignant astrocytoma in elderly patients: where do we stand?. 2013 , 26, 693-700		7
436	Glutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiforme. <i>Neuro-Oncology</i> , 2013 , 15, 618-25	1	51
435	Anticancer effects of niclosamide in human glioblastoma. 2013 , 19, 4124-36		107
434	O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas. 2013 , 4, e876		117
433	Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma. 2013 , 4, e458		104
432	Standards of care for treatment of recurrent glioblastoma--are we there yet?. <i>Neuro-Oncology</i> , 2013 , 15, 4-27	1	432

431	Moderne Therapiestrategien bei hirneigenen glialen Tumoren. 2013 , 16, 32-43	
430	Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma. 2013 , 37, 264-71	18
429	Expression of 5-Methylguanine-DNA Methyltransferase Examined by Alkyl-Transfer Assays, Methylation-Specific PCR and Western Blots in Tumors and Matched Normal Tissue. 2013 , 4, 919-931	12
428	DNA Damage, DNA Repair and Cancer. 2013 ,	26
427	Integrated analysis of mismatch repair system in malignant astrocytomas. 2013 , 8, e76401	17
426	Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunities. 2013 , 6, 931-42	15
425	Topoisomerase Therapy in the Treatment of Brain Tumors. 2013 ,	1
424	MicroRNAs in Primary Brain Tumors: Functional Impact and Potential Use for Diagnostic Purposes. 2014 , 25-38	
423	The predictive but not prognostic value of MGMT promoter methylation status in elderly glioblastoma patients: a meta-analysis. 2014 , 9, e85102	28
422	Performance evaluation of kits for bisulfite-conversion of DNA from tissues, cell lines, FFPE tissues, aspirates, lavages, effusions, plasma, serum, and urine. 2014 , 9, e93933	85
421	NEO212, temozolomide conjugated to perillyl alcohol, is a novel drug for effective treatment of a broad range of temozolomide-resistant gliomas. 2014 , 13, 2004-17	38
420	Anatomical specificity of O6-methylguanine DNA methyltransferase protein expression in glioblastomas. <i>Journal of Neuro-Oncology</i> , 2014 , 120, 331-7	4.8 18
419	Exo1 independent DNA mismatch repair involves multiple compensatory nucleases. 2014 , 21, 55-64	19
418	Detection of circulating tumor cells in the cerebrospinal fluid of a patient with a solitary metastasis from breast cancer: A case report. 2014 , 7, 2110-2112	2
417	ATM regulates 3-methylpurine-DNA glycosylase and promotes therapeutic resistance to alkylating agents. 2014 , 4, 1198-213	43
416	Prediction of methylguanine methyltransferase promoter methylation in glioblastoma using dynamic contrast-enhanced magnetic resonance and diffusion tensor imaging. 2014 , 121, 367-73	62
415	Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. <i>Neuro-Oncology</i> , 2014 , 16, 1630-8	59
414	Glioblastoma: background, standard treatment paradigms, and supportive care considerations. 2014 , 42, 171-82	43

413	High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2014 , 25 Suppl 3, iii93-101		357
412	Residual tumor volume and patient survival following reoperation for recurrent glioblastoma. 2014 , 121, 802-9		43
411	Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial. 2014 , 2, 68		22
410	Advances in Oncolytic Virotherapy for Brain Tumors. 2014 , 137-151		1
409	The role of inflammation in brain cancer. 2014 , 816, 75-105		47
408	Clinical Trials Using LV-P140K-MGMT for Gliomas. 2014 , 379-391		1
407	TET enzymatic oxidation of 5-methylcytosine, 5-hydroxymethylcytosine and 5-formylcytosine. 2014 , 764-765, 18-35		37
406	Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain. 2014 , 16, 273-9		6
405	Tumor-associated mutations in O ⁶ -methylguanine DNA-methyltransferase (MGMT) reduce DNA repair functionality. 2014 , 53, 201-10		4
404	A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2014 , 116, 315-24	4.8	30
403	Ependymoma stem cells are highly sensitive to temozolomide in vitro and in orthotopic models. <i>Neuro-Oncology</i> , 2014 , 16, 1067-77	1	21
402	Methylation-specific multiplex ligation-dependent probe amplification identifies promoter methylation events associated with survival in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2014 , 117, 243-51 ⁸	4.8	7
401	Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2014 , 116, 487-96	4.8	43
400	Precision treatment for cancer: role of prognostic and predictive markers. 2014 , 51, 30-45		22
399	Using the molecular classification of glioblastoma to inform personalized treatment. 2014 , 232, 165-77		174
398	Fas, FasL, and cleaved caspases 8 and 3 in glioblastomas: a tissue microarray-based study. 2014 , 210, 267-73		29
397	Pathology of gliomas and developments in molecular testing. 2014 , 26, 377-84		4
396	Immunological challenges for peptide-based immunotherapy in glioblastoma. 2014 , 40, 248-58		38

395	Epigenetic primer for diagnostic applications: a window into personalized medicine. 2014 , 11, 323-337		2
394	Epigenetic Changes in Gliomas. 2014 , 23-45		
393	The evolving role of molecular markers in the diagnosis and management of diffuse glioma. 2014 , 20, 5601-11		44
392	Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation. <i>Neuro-Oncology</i> , 2014 , 16, 1607-17	1	25
391	(11)C-methinine uptake correlates with MGMT promoter methylation in nonenhancing gliomas. 2014 , 125, 212-6		30
390	Recognizing and correcting failures in glioblastoma treatment. 2014 , 32, 299-302		5
389	Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. 2014 , 30, 326-39		179
388	Interferon- γ induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells. 2014 , 13, 948-61		40
387	Stability of the CpG island methylator phenotype during glioma progression and identification of methylated loci in secondary glioblastomas. 2014 , 14, 506		17
386	Molecular neuro-oncology and the challenge of the blood-brain barrier. 2014 , 41, 438-445		11
385	Personalized pharmacogenomics: predicting efficacy and adverse drug reactions. 2014 , 15, 349-70		104
384	[Interdisciplinary neuro-oncology: part 1: diagnostics and operative therapy of primary brain tumors]. 2014 , 85, 965-75		1
383	Combination treatment with theranostic nanoparticles for glioblastoma sensitization to TMZ. 2014 , 16, 680-9		32
382	Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide. 2014 , 14, 151		50
381	MGMT testing--the challenges for biomarker-based glioma treatment. <i>Nature Reviews Neurology</i> , 2014 , 10, 372-85	15	316
380	Current concepts in the surgical management of glioma patients. 2014 , 26, 385-94		23
379	Epigenetic biomarkers in urological tumors: A systematic review. 2014 , 342, 264-74		76
378	DNA methylation biomarkers: cancer and beyond. 2014 , 5, 821-64		180

377	Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses. <i>Neurosurgery</i> , 2014 , 61 Suppl 1, 74-83	3.2	12
376	Multidrug Efflux Pumps Attenuate the Effect of MGMT Inhibitors. 2015 , 12, 3924-34		14
375	Using the apparent diffusion coefficient to identifying MGMT promoter methylation status early in glioblastoma: importance of analytical method. 2015 , 62, 92-8		26
374	Glioma. 2015 , 1, 15017		368
373	Dose-dense temozolomide: is it still promising?. 2015 , 55, 38-49		12
372	Expression profiling of O(6) methylguanine-DNA-methyl transferase in prolactinomas: a correlative study of promoter methylation and pathological features in 136 cases. 2015 , 15, 644		6
371	Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas. 2015 , 35, 324-35		40
370	Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choice. 2015 , 121, 3428-34		28
369	Imaging Genomics of Glioblastoma: Biology, Biomarkers, and Breakthroughs. 2015 , 24, 155-63		12
368	Genetic Characterization of Ten-Eleven-Translocation Methylcytosine Dioxygenase Alterations in Human Glioma. 2015 , 6, 832-42		19
367	Heterogeneous DNA Methylation Patterns in the GSTP1 Promoter Lead to Discordant Results between Assay Technologies and Impede Its Implementation as Epigenetic Biomarkers in Breast Cancer. 2015 , 6, 878-900		14
366	MGMT promoter methylation and glioblastoma: a comparison of analytical methods and of tumor specimens. 2015 , 30, e208-16		13
365	The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma. 2015 , 2015, 604719		10
364	Targeting DNA Repair Mechanisms to Treat Glioblastoma. 2015 ,		5
363	Identifying core gene modules in glioblastoma based on multilayer factor-mediated dysfunctional regulatory networks through integrating multi-dimensional genomic data. 2015 , 43, 1997-2007		26
362	Malignant Glioma: Viewpoint Chemotherapy. 2015 , 279-293		
361	Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review). 2015 , 47, 417-28		77
360	Diagnostic, prognostic and predictive relevance of molecular markers in gliomas. 2015 , 41, 694-720		72

359	Impact of delays in initiating postoperative chemoradiation while determining the MGMT promoter-methylation statuses of patients with primary glioblastoma. 2015 , 15, 558		21
358	Advances in the treatment of newly diagnosed glioblastoma. 2015 , 13, 293		31
357	Treatment considerations for MGMT-unmethylated glioblastoma. 2015 , 15, 507		36
356	Activity of 2-aryl-2-(3-indolyl)acetohydroxamates against drug-resistant cancer cells. 2015 , 58, 2206-20		40
355	Assessing MGMT methylation status and its current impact on treatment in glioblastoma. 2015 , 4, 47-52		19
354	Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients. <i>Journal of Neuro-Oncology</i> , 2015 , 122, 441-50	4.8	30
353	Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center. <i>Journal of Neuro-Oncology</i> , 2015 , 122, 189-96	4.8	40
352	Function and information content of DNA methylation. 2015 , 517, 321-6		1207
351	O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents. 2015 , 112, 523-31		86
350	Aberrations in DNA methylation are detectable during remission of acute lymphoblastic leukemia and predict patient outcome. 2015 , 7, 35-45		4
349	The future of high-grade glioma: Where we are and where are we going. 2015 , 6, S9-S44		22
348	Chemoresistance and chemotherapy targeting stem-like cells in malignant glioma. 2015 , 853, 111-38		36
347	Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene expression data. 2015 , 6, e1753		85
346	Implication of a Chromosome 15q15.2 Locus in Regulating UBR1 and Predisposing Smokers to MGMT Methylation in Lung. 2015 , 75, 3108-17		5
345	Clinical applications of iron oxide nanoparticles for magnetic resonance imaging of brain tumors. 2015 , 10, 993-1018		79
344	Molecular heterogeneity in glioblastoma: potential clinical implications. <i>Frontiers in Oncology</i> , 2015 , 5, 55	5.3	125
343	Treatment of elderly patients with glioblastoma: a systematic evidence-based analysis. 2015 , 72, 589-96		59
342	Contemporary proteomic strategies for clinical epigenetic research and potential impact for the clinic. 2015 , 12, 197-212		2

341	ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells. 2015 , 13, 74	22
340	miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferase. 2015 , 13, 69	30
339	Stem Cell Biology in Neoplasms of the Central Nervous System. 2015 ,	2
338	Molecular and Genomic Alterations in Glioblastoma Multiforme. 2015 , 185, 1820-33	101
337	O(6) -methylguanine DNA methyltransferase repairs platinum-DNA adducts following cisplatin treatment and predicts prognoses of nasopharyngeal carcinoma. 2015 , 137, 1291-305	19
336	Nanomedicine to overcome radioresistance in glioblastoma stem-like cells and surviving clones. 2015 , 36, 236-52	35
335	In vitro and in vivo studies of temozolomide loading in zeolite structures as drug delivery systems for glioblastoma. 2015 , 5, 28219-28227	17
334	MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. 2015 , 21, 2057-64	206
333	Epigenetic landscape correlates with genetic subtype but does not predict outcome in childhood acute lymphoblastic leukemia. 2015 , 10, 717-26	17
332	ESCI award lecture: regulation, function and biomarker potential of DNA methylation. 2015 , 45, 288-93	8
331	IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy. <i>Journal of Neuro-Oncology</i> , 2015 , 124, 493-500	4.8 6
330	Bisulfite Conversion of DNA from Tissues, Cell Lines, Buffy Coat, FFPE Tissues, Microdissected Cells, Swabs, Sputum, Aspirates, Lavages, Effusions, Plasma, Serum, and Urine. 2017 , 1589, 139-159	13
329	Fungal metabolite ophiobolin A as a promising anti-glioma agent: In vivo evaluation, structure-activity relationship and unique pyrrolylation of primary amines. 2015 , 25, 4544-8	27
328	Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. 2016 , 108,	66
327	Molecular Pathology of Nervous System Tumors. 2015 ,	1
326	Imaging genomics of Glioblastoma: state of the art bridge between genomics and neuroradiology. 2015 , 25, 141-53	34
325	. 2015 , 52, 1887-1887	7
324	MGMT critical DNA repair gene target for chemotherapy resistance. 2016 , 55-82	2

323	Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing. 2016 , 11, e0162105	9
322	Evolving Molecular Genetics of Glioblastoma. 2016 , 129, 464-71	32
321	New perspectives in glioblastoma antiangiogenic therapy. 2016 , 20, 109-18	18
320	Role of Concurrent Methylation Pattern of MGMT, TP53 and CDKN2A Genes in the Prognosis of High Grade Glioma. 2016 , 07,	2
319	Detection limits of 405 nm and 633 nm excited PpIX fluorescence for brain tumor detection during stereotactic biopsy. 2016 ,	
318	Environment-sensitive Fluorescent Turn-on Chemical Probe for the Specific Detection of O-Methylguanine-DNA Methyltransferase (MGMT) in Living Cells. 2016 , 63, 688-693	4
317	Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009. 2016 , 122, 2206-15	52
316	405nm versus 633nm for protoporphyrin IX excitation in fluorescence-guided stereotactic biopsy of brain tumors. 2016 , 9, 901-12	27
315	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. 2016 , 1, e000097	59
314	Incremental Prognostic Value of ADC Histogram Analysis over MGMT Promoter Methylation Status in Patients with Glioblastoma. 2016 , 281, 175-84	37
313	Chemotherapy for intracranial ependymoma in adults. 2016 , 16, 287	17
312	5,10b-Ethanophenanthridine amaryllidaceae alkaloids inspire the discovery of novel bicyclic ring systems with activity against drug resistant cancer cells. 2016 , 120, 313-28	13
311	Anticancer drug-loaded hydrogels as drug delivery systems for the local treatment of glioblastoma. 2016 , 243, 29-42	134
310	Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas. 2016 , 37, 13571-13579	10
309	DNA Methylation in Acquired Drug Resistance. 2016 , 161-175	
308	The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis. 2016 , 14, 261	39
307	Deletion and low expression of NFKBIA are associated with poor prognosis in lower-grade glioma patients. <i>Scientific Reports</i> , 2016 , 6, 24160	4.9 10
306	Why one-size-fits-all vaso-modulatory interventions fail to control glioma invasion: in silico insights. <i>Scientific Reports</i> , 2016 , 6, 37283	4.9 32

305	Glioblastoma in the elderly: making sense of the evidence. 2016 , 3, 77-86		9
304	Role of irradiation for patients over 80 years old with glioblastoma: a retrospective cohort study. <i>Journal of Neuro-Oncology</i> , 2016 , 129, 347-53	4.8	8
303	Experimental Therapeutic Trial Design for Pediatric Brain Tumors. 2016 , 31, 1421-32		
302	Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients. 2016 , 16, 81		30
301	Success and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions. 2016 , 26, 281-98		16
300	Chemoradiotherapy: Radiation Total Dose and Fractionation. 2016 , 41-62		
299	Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the 'integrated' diagnosis approach. 2016 , 69, 686-94		17
298	DNA damage and the balance between survival and death in cancer biology. 2016 , 16, 20-33		624
297	Glioblastoma. 2016 , 134, 381-97		160
296	Second surgery for recurrent glioblastoma: A concise overview of the current literature. 2016 , 142, 60-64		50
295	Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide. <i>Neuro-Oncology</i> , 2016 , 18, 962-73	1	21
294	Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma. 2016 , 125, 7-16		19
293	How to train glioma cells to die: molecular challenges in cell death. <i>Journal of Neuro-Oncology</i> , 2016 , 126, 377-84	4.8	23
292	Protein sensing in living cells by molecular rotor-based fluorescence-switchable chemical probes. 2016 , 7, 301-307		65
291	Learning MRI-based classification models for MGMT methylation status prediction in glioblastoma. 2017 , 140, 249-257		51
290	Multidrug resistance in glioblastoma stem-like cells: Role of the hypoxic microenvironment and adenosine signaling. 2017 , 55, 140-151		73
289	On glioblastoma and the search for a cure: where do we stand?. 2017 , 74, 2451-2466		37
288	Temozolomide in the Era of Precision Medicine. 2017 , 77, 823-826		61

287	Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities. 2017 , 9, 34		77
286	Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: a population-based study in China. 2017 , 24, 215-220		7
285	European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. 2017 , 18, e315-e329		599
284	HP1 β s highly expressed in glioma cells and facilitates cell proliferation and survival. 2017 , 490, 415-422		4
283	Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2017 , 133, 193-201	4.8	20
282	O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors. 2017 , 46, 758-763		20
281	Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors. 2017 , 29, 826-830		13
280	Central nervous system gliomas. 2017 , 113, 213-234		84
279	Evaluation of non-supervised MALDI mass spectrometry imaging combined with microproteomics for glioma grade III classification. 2017 , 1865, 875-890		27
278	Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O-Methylguanine-DNA Methyltransferase Biomarker Analyses. 2017 , 35, 343-351		77
277	Treatment of Glioblastoma in Older Adults. 2017 , 19, 81		29
276	HB-EGF is associated with DNA damage and Mcl-1 turnover in human glioma cell lines treated by Temozolomide. 2017 , 493, 1377-1383		3
275	Association between MGMT Promoter Methylation and Risk of Breast and Gynecologic Cancers: A Systematic Review and Meta-Analysis. <i>Scientific Reports</i> , 2017 , 7, 12783	4.9	4
274	Genomic Studies Reveal New Aspects of the Biology of DNA Damaging Agents. 2017 , 18, 2368-2375		7
273	A 4-miRNAs signature predicts survival in glioblastoma multiforme patients. 2017 , 20, 443-452		19
272	Molecular Pathology of Glioblastoma- An Update. 2017 , 19-55		
271	Cell Signaling Pathways in Brain Tumors. 2017 , 26, 15-26		3
270	The biology and mathematical modelling of glioma invasion: a review. 2017 , 14,		98

269	What Stressors Cause Cancer and When?. 2017 , 1-60		1
268	Recent developments in predictive biomarkers of pediatric glioma. 2017 , 14, 497-500		1
267	Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma. 2017 , 42, 341-347		19
266	Importance of biomarkers in glioblastomas patients receiving local BCNU wafer chemotherapy. 2017 , 10, 16		7
265	Regulation of DNA Alkylation Damage Repair: Lessons and Therapeutic Opportunities. 2017 , 42, 206-218		60
264	Role of STAT3 in Genesis and Progression of Human Malignant Gliomas. 2017 , 54, 5780-5797		35
263	Remission spectrometry for blood vessel detection during stereotactic biopsy of brain tumors. 2017 , 10, 1080-1094		9
262	Recurrent Glioblastoma: Combination of High Cerebral Blood Flow with MGMT Promoter Methylation Is Associated with Benefit from Low-Dose Temozolomide Rechallenge at First Recurrence. 2017 , 282, 212-221		9
261	Identification of key genes in glioma CpG island methylator phenotype via network analysis of gene expression data. 2017 , 16, 9503-9511		2
260	The Response to Chemo Radiation Therapy in Unresectable Glioblastoma Multiforme Patients in Relation to MGMT Promoter Methylation Status: A Study from a Single Saudi Center. 2017 , 03,		
259	Clinical Applications of Contrast-Enhanced Perfusion MRI Techniques in Gliomas: Recent Advances and Current Challenges. 2017 , 2017, 7064120		56
258	Chemotherapeutic Drugs: DNA Damage and Repair in Glioblastoma. <i>Cancers</i> , 2017 , 9,	6.6	42
257	The rs16906252:C>T SNP is not associated with increased overall survival or temozolomide response in a Han-Chinese glioma cohort. 2017 , 12, e0178842		2
256	The Process and Regulatory Components of Inflammation in Brain Oncogenesis. 2017 , 7,		51
255	Is the prognostic significance of O6-methylguanine- DNA methyltransferase promoter methylation equally important in glioblastomas of patients from different continents? A systematic review with meta-analysis. <i>Cancer Management and Research</i> , 2017 , 9, 411-425	3.6	10
254	Inhibition of JMJD6 expression reduces the proliferation, migration and invasion of neuroglioma stem cells. 2017 , 64, 700-708		13
253	Nanotechnology in neurosurgical oncology. 2017 , 139-170		2
252	Co-targeting the tumor endothelium and P-selectin-expressing glioblastoma cells leads to a remarkable therapeutic outcome. 2017 , 6,		32

251	Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics. 2018 , 25, 143-171		23
250	Transcriptional control of O -methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma. 2018 , 144, 780-790		15
249	National Trends for Reoperation in Older Patients with Glioblastoma. 2018 , 113, e179-e189		13
248	NEO212 Inhibits Migration and Invasion of Glioma Stem Cells. 2018 , 17, 625-637		16
247	Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics. 2018 , 28, 2115-2123		37
246	Temporal stability of MGMT promoter methylation in glioblastoma patients undergoing STUPP protocol. <i>Journal of Neuro-Oncology</i> , 2018 , 137, 233-240	4.8	6
245	The FDA NIH Biomarkers, Endpoints, and other Tools (BEST) resource in neuro-oncology. <i>Neuro-Oncology</i> , 2018 , 20, 1162-1172	1	38
244	Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide). <i>Scientific Reports</i> , 2018 , 8, 6704	4.9	33
243	Neutrophilia as a biomarker for overall survival in newly diagnosed high-grade glioma patients undergoing chemoradiation. 2018 , 10, 47-52		21
242	Multiregional radiomics features from multiparametric MRI for prediction of MGMT methylation status in glioblastoma multiforme: A multicentre study. 2018 , 28, 3640-3650		85
241	MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme. 2018 , 14, 699-707		18
240	HP1βs highly expressed in glioma cells and facilitates cell proliferation and survival. 2017 , 20, 453-460		3
239	Gemcitabine and glioblastoma: challenges and current perspectives. 2018 , 23, 416-423		27
238	Clinical implications of in silico mathematical modeling for glioblastoma: a critical review. <i>Journal of Neuro-Oncology</i> , 2018 , 136, 1-11	4.8	11
237	A Summary of the Biological Processes, Disease-Associated Changes, and Clinical Applications of DNA Methylation. 2018 , 1708, 3-30		24
236	Integrating Molecular Diagnostics With Surgical Neuropathology. 2018 , 71-89		1
235	Astrocytic and Oligodendroglial Tumors. 2018 , 91-123		0
234	Local alkylating chemotherapy applied immediately after 5-ALA guided resection of glioblastoma does not provide additional benefit. <i>Journal of Neuro-Oncology</i> , 2018 , 136, 273-280	4.8	17

233	O-methylguanine-DNA-methyltransferase immunostaining intensity in glioblastoma. 2018 , 52, 116-119		
232	Chemical exchange saturation transfer MRI serves as predictor of early progression in glioblastoma patients. <i>Oncotarget</i> , 2018 , 9, 28772-28783	3.3	44
231	Tumor-specific methylations in circulating cell-free DNA as clinically applicable markers with potential to substitute mutational analyses. 2018 , 18, 1011-1019		7
230	A comprehensive review of available omics data resources and molecular profiling for precision glioma studies. 2019 , 10, 3-9		5
229	Ten genes associated with MGMT promoter methylation predict the prognosis of patients with glioma. 2019 , 41, 908-916		2
228	Inhibition of glioblastoma cell proliferation, invasion, and mechanism of action of a novel hydroxamic acid hybrid molecule. 2018 , 4, 41		24
227	The potential for remodelling the tumour vasculature in glioblastoma. 2018 , 136-137, 49-61		9
226	Glioblastoma Chemoresistance: The Double Play by Microenvironment and Blood-Brain Barrier. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	73
225	Real-time methylation-specific PCR for the evaluation of methylation status of MGMT gene in glioblastoma. <i>Oncotarget</i> , 2018 , 9, 27728-27735	3.3	9
224	Gene Promoter Methylation Status - Assessment of Two Pyrosequencing Kits and Three Methylation-specific PCR Methods for their Predictive Capacity in Glioblastomas. 2018 , 15, 437-446		25
223	Pan-Cancer Landscape of Aberrant DNA Methylation across Human Tumors. 2018 , 25, 1066-1080.e8		104
222	Prognostic Factors and Survival of Gliomatosis Cerebri: A Systematic Review and Meta-Analysis. 2018 , 120, e818-e854		7
221	The Genomic Basis of Tumor Regression in Tasmanian Devils (<i>Sarcophilus harrisii</i>). 2018 , 10, 3012-3025		21
220	FM19G11 inhibits O -methylguanine DNA-methyltransferase expression under both hypoxic and normoxic conditions. 2018 , 7, 3292		5
219	Emergence of exosomal DNA in molecular neuropathology. 2018 , 42, 9-22		1
218	Epigenetic mechanisms as a new approach in cancer treatment: An updated review. 2018 , 5, 304-311		100
217	Coaxial extrusion bioprinted shell-core hydrogel microfibers mimic glioma microenvironment and enhance the drug resistance of cancer cells. 2018 , 171, 291-299		45
216	The Clinical Significance of O-Methylguanine-DNA Methyltransferase Promoter Methylation Status in Adult Patients With Glioblastoma: A Meta-analysis. 2018 , 9, 127		22

215	Molecular biology as a tool for the treatment of cancer. 2018 , 18, 457-464		16
214	Epigenetic Modifications as Biomarkers of Tumor Development, Therapy Response, and Recurrence across the Cancer Care Continuum. <i>Cancers</i> , 2018 , 10,	6.6	39
213	The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space. 2018 , 24, 1611-1624		124
212	Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2018 , 140, 559-568	4.8	7
211	Evaluation of bisulfite kits for DNA methylation profiling in terms of DNA fragmentation and DNA recovery using digital PCR. 2018 , 13, e0199091		40
210	Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas. 2019 , 25, 314-322		20
209	Whole brain radiotherapy with concurrent temozolomide in multifocal and/or multicentric newly diagnosed glioblastoma. 2019 , 68, 39-44		13
208	Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients. <i>Scientific Reports</i> , 2019 , 9, 11125	4.9	13
207	Codelivery of paclitaxel and temozolomide through a photopolymerizable hydrogel prevents glioblastoma recurrence after surgical resection. 2019 , 309, 72-81		45
206	Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2. 2019 , 142, 2352-2366		60
205	The potential of cerebrospinal fluid-based liquid biopsy approaches in CNS tumors. <i>Neuro-Oncology</i> , 2019 , 21, 1509-1518	1	25
204	Predictive markers for MGMT promoter methylation in glioblastomas. 2019 , 42, 867-876		8
203	Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma. <i>Neuro-Oncology</i> , 2019 , 21, 1141-1149		6
202	MPC1 deletion is associated with poor prognosis and temozolomide resistance in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019 , 144, 293-301	4.8	13
201	DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas. 2019 , 78, 128-141		47
200	Lnc-TALC promotes O-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. 2019 , 10, 2045		73
199	Gliomatosis Cerebri Among Children and Adolescents: An Individual-Patient Data Meta-analysis of 182 Patients. 2019 , 34, 394-401		1
198	MicroRNAs, Hypoxia and the Stem-Like State as Contributors to Cancer Aggressiveness. <i>Frontiers in Genetics</i> , 2019 , 10, 125	4.5	29

197	Tumor Genetics and Their Outcomes on Surgery and Survival. 2019 , 191-203		
196	O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET). 2019 , 51, 595-599		16
195	Early response assessment of glioma patients to definitive chemoradiotherapy using chemical exchange saturation transfer imaging at 7 T. 2019 , 50, 1268-1277		33
194	Preoperative MRI-radiomics features improve prediction of survival in glioblastoma patients over MGMT methylation status alone. <i>Oncotarget</i> , 2019 , 10, 660-672	3.3	25
193	Basics of Brain Tumor Biology for Clinicians. 2019 , 7-19		
192	MGMT Testing in Glioblastomas: Pitfalls and Opportunities. 2019 , 42, 117-122		9
191	DNA damage repair alterations modulate M2 polarization of microglia to remodel the tumor microenvironment via the p53-mediated MDK expression in glioma. 2019 , 41, 185-199		44
190	Changes of O-Methylguanine DNA Methyltransferase (MGMT) Promoter Methylation in Glioblastoma Relapse-A Meta-Analysis Type Literature Review. <i>Cancers</i> , 2019 , 11,	6.6	16
189	Updates in the Neuroimaging and WHO Classification of Primary CNS Gliomas: A Review of Current Terminology, Diagnosis, and Clinical Relevance From a Radiologic Prospective. 2019 , 28, 73-84		2
188	Targeting DNA repair in gliomas. 2019 , 32, 878-885		5
187	The central nervous system tumor methylation classifier changes neuro-oncology practice for challenging brain tumor diagnoses and directly impacts patient care. 2019 , 11, 185		25
186	20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma. 2019 , 110, 389-400		23
185	Transcriptional and epigenetic mechanisms underlying astrocyte identity. 2019 , 174, 36-52		12
184	Mifepristone Overcomes Tumor Resistance to Temozolomide Associated with DNA Damage Repair and Apoptosis in an Orthotopic Model of Glioblastoma. <i>Cancers</i> , 2018 , 11,	6.6	7
183	Apparent Diffusion Coefficient as a Predictive Biomarker for Survival in Patients with Treatment-Naive Glioblastoma Using Quantitative Multiparametric Magnetic Resonance Profiling. 2019 , 122, e812-e820		8
182	Clinical and in vitro studies of the correlation between MGMT and the effect of streptozocin in pancreatic NET. 2019 , 83, 43-52		4
181	Chemotherapy sensitization of glioblastoma by focused ultrasound-mediated delivery of therapeutic liposomes. 2019 , 295, 130-139		36
180	A novel analytical model of MGMT methylation pyrosequencing offers improved predictive performance in patients with gliomas. 2019 , 32, 4-15		19

179	Do we really know who has an methylated glioma? Results of an international survey regarding use of analyses for glioma. 2020 , 7, 68-76		12
178	Inhibition of motility by NEO100 through the calpain-1/RhoA pathway. 2019 , 1-12		2
177	Glioma Imaging. 2020 ,		2
176	Imaging signatures of glioblastoma molecular characteristics: A radiogenomics review. 2020 , 52, 54-69		26
175	Deep Learning of Imaging Phenotype and Genotype for Predicting Overall Survival Time of Glioblastoma Patients. 2020 , 39, 2100-2109		18
174	Expression of Alpha-type Platelet-derived Growth Factor Receptor-influenced Genes Predicts Clinical Outcome in Glioma. <i>Translational Oncology</i> , 2020 , 13, 233-240	4.9	2
173	Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma. 2020 , 11, 19		26
172	Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer. 2020 , 82, 101935		7
171	Clinical characterization of glioblastoma patients living longer than 2 years: A retrospective analysis of two Italian institutions. 2021 , 17, 273-279		1
170	Automatic Prediction of MGMT Status in Glioblastoma via Deep Learning-Based MR Image Analysis. 2020 , 2020, 9258649		11
169	Machine learning-based radiomic, clinical and semantic feature analysis for predicting overall survival and MGMT promoter methylation status in patients with glioblastoma. 2020 , 74, 161-170		10
168	The Role of Imaging Biomarkers Derived From Advanced Imaging and Radiomics in the Management of Brain Tumors. <i>Frontiers in Oncology</i> , 2020 , 10, 559946	5.3	1
167	MGMT Promoter Methylation Status Is Not Related to Histological or Radiological Features in IDH Wild-type Glioblastomas. 2020 , 79, 855-862		3
166	Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts. 2020 , 79, 843-854		13
165	Prediction of MGMT Status for Glioblastoma Patients Using Radiomics Feature Extraction From F-DOPA-PET Imaging. 2020 , 108, 1339-1346		15
164	Deep learning for glioblastoma segmentation using preoperative magnetic resonance imaging identifies volumetric features associated with survival. 2020 , 162, 3067-3080		1
163	Analysis of DNA methylation using pyrosequencing. 2020 , 37-62		1
162	Tunneling Nanotubes Mediate Adaptation of Glioblastoma Cells to Temozolomide and Ionizing Radiation Treatment. 2020 , 23, 101450		14

161	Glioma progression is suppressed by Naringenin and APO2L combination therapy via the activation of apoptosis in vitro and in vivo. 2020 , 38, 1743-1754		2
160	MGMT Status as a Clinical Biomarker in Glioblastoma. 2020 , 6, 380-391		43
159	CRISPR-mediated promoter de/methylation technologies for gene regulation. 2020 , 43, 705-713		2
158	Role for Metallothionein-3 in the Resistance of Human U87 Glioblastoma Cells to Temozolomide. 2020 , 5, 17900-17907		2
157	The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis. 2020 , 20, 897		8
156	Temozolomide-Induced RNA Interactome Uncovers Novel LncRNA Regulatory Loops in Glioblastoma. <i>Cancers</i> , 2020 , 12,	6.6	4
155	IGFBP3 gene promoter methylation analysis and its association with clinicopathological characteristics of colorectal carcinoma. 2020 , 47, 6919-6927		3
154	The different role of YKL-40 in glioblastoma is a function of MGMT promoter methylation status. 2020 , 11, 668		6
153	Biologically Active TNIIIA2 Region in Tenascin-C Molecule: A Major Contributor to Elicit Aggressive Malignant Phenotypes From Tumors/Tumor Stroma. 2020 , 11, 610096		4
152	PLEKHG5 regulates autophagy, survival and MGMT expression in U251-MG glioblastoma cells. <i>Scientific Reports</i> , 2020 , 10, 21858	4.9	2
151	Development of a peptide-based delivery platform for targeting malignant brain tumors. 2020 , 252, 120105		10
150	Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment. 2020 , 14, 1016-1027		12
149	Molecular Characterization of Astrocytoma Progression Towards Secondary Glioblastomas Utilizing Patient-Matched Tumor Pairs. <i>Cancers</i> , 2020 , 12,	6.6	1
148	A "Clickable" Probe for Active MGMT in Glioblastoma Demonstrates Two Discrete Populations of MGMT. <i>Cancers</i> , 2020 , 12,	6.6	3
147	Drug penetration through the bloodBrain barrier after radiotherapy: New approaches to bypass glioblastoma chemoresistance. 2021 , 689-705		
146	Evolutionary Mechanisms of Cancer Suggest Rational Therapeutic Approaches. 2021 , 161, 362-371		2
145	Tumors of the Central Nervous System. 2021 , 121-145		
144	Low concentrations of vorinostat decrease EB1 expression in GBM cells and affect microtubule dynamics, cell survival and migration. <i>Oncotarget</i> , 2021 , 12, 304-315	3.3	1

143	The Survival Benefit of Postoperative Bacterial Infections in Patients With Glioblastoma Multiforme: Myth or Reality?. 2021 , 12, 615593		1
142	IDH1 Non-Canonical Mutations and Survival in Patients with Glioma. 2021 , 11,		6
141	Genomic Space of in Human Glioma Revisited: Novel Motifs, Regulatory RNAs, NRF1, 2, and CTCF Involvement in Gene Expression. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
140	Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients. 2021 , 13, 52		4
139	Targeting Genome Stability in Melanoma-A New Approach to an Old Field. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
138	Negative allosteric modulators of metabotropic glutamate receptor 3 target the stem-like phenotype of glioblastoma. 2021 , 20, 166-174		1
137	Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications. 2021 , 19, 513-537		10
136	Glioblastoma Primary Cells Retain the Most Copy Number Alterations That Predict Poor Survival in Glioma Patients. <i>Frontiers in Oncology</i> , 2021 , 11, 621432	5.3	
135	Molecular biological investigation of temozolomide and KC7F2 combination in U87MG glioma cell line. 2021 , 776, 145445		0
134	Diagnosis and Individualized Treatment of Secondary Central Nervous System Lymphoma: A Case Report. 2021 , 14, 3167-3175		0
133	Prolonged survival after laser interstitial thermal therapy in glioblastoma. 2021 , 12, 228		1
132	Transcriptional Pausing and Activation at Exons-1 and -2, Respectively, Mediate the Gene Expression in Human Glioblastoma Cells. 2021 , 12,		
131	Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives. 2021 , 26, 865-878		7
130	[Next generation sequencing in histopathology : Applications and methodological challenges]. 2021 , 42, 363-368		
129	Extent of MGMT promoter methylation modifies the effect of temozolomide on overall survival in patients with glioblastoma: a regional cohort study in Southeast Scotland.		
128	Glioblastoma multiforme prognosis: MRI missing modality generation, segmentation and radiogenomic survival prediction. 2021 , 91, 101906		5
127	Phosphorous Magnetic Resonance Spectroscopy and Molecular Markers in IDH1 Wild Type Glioblastoma. <i>Cancers</i> , 2021 , 13,	6.6	3
126	Immunohistochemical expression of MGMT in gliomas and its role in ascertaining patient survival. 2021 , 94, 318-324		0

125 .1

124	Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastoma. 2021 , 10, CNS74		1
123	Valproic Acid Enhanced Temozolomide-Induced Anticancer Activity in Human Glioma Through the p53-PUMA Apoptosis Pathway. <i>Frontiers in Oncology</i> , 2021 , 11, 722754	5.3	2
122	Predictive value of MGMT promoter methylation on the survival of TMZ treated -mutant glioblastoma. 2021 , 18, 272-282		6
121	Treatment of Brain Tumors. 2014 , 169-194		1
120	Adult High-Grade (Diffuse) Glioma. 2015 , 77-93		2
119	Molecular-Genetic Classification of Gliomas and Its Practical Application to Diagnostic Neuropathology. 2017 , 73-100		1
118	MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017 , 133, 615-622	4.8	9
117	Real-Time Methylation-Specific Polymerase Chain Reaction for MGMT Promoter Methylation Clinical Testing in Glioblastoma: An Alternative Detection Method for a Heterogeneous Process. 2017 , 148, 296-307		3
116	Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. 2012 , 122, 253-66		108
115	Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. 2012 , 7, e33449		96
114	DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma. 2012 , 7, e35857		27
113	Altered expression of MGMT in high-grade gliomas results from the combined effect of epigenetic and genetic aberrations. 2013 , 8, e58206		27
112	Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging. 2013 , 8, e67911		27
111	MiR-221/222 target the DNA methyltransferase MGMT in glioma cells. 2013 , 8, e74466		71
110	Fluorogenic Real-Time Reporters of DNA Repair by MGMT, a Clinical Predictor of Antitumor Drug Response. 2016 , 11, e0152684		17
109	MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma. 2016 , 11, e0156422		12
108	UBE2T promotes glioblastoma invasion and migration via stabilizing GRP78 and regulating EMT. 2020 , 12, 10275-10289		15

107	miR-29c contribute to glioma cells temozolomide sensitivity by targeting O6-methylguanine-DNA methyltransferases indirectly. <i>Oncotarget</i> , 2016 , 7, 50229-50238	3.3	30
106	Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial. <i>Oncotarget</i> , 2016 , 7, 61916-61929	3.3	34
105	Dissecting DNA repair in adult high grade gliomas for patient stratification in the post-genomic era. <i>Oncotarget</i> , 2014 , 5, 5764-81	3.3	7
104	Molecular analysis of the dual targeting of the epidermal growth factor receptor and the O-methylguanine-DNA methyltransferase with a double arm hybrid molecule. <i>Oncotarget</i> , 2018 , 9, 35041-35053	3.3	3
103	The HIV-derived protein Vpr52-96 has anti-glioma activity in vitro and in vivo. <i>Oncotarget</i> , 2016 , 7, 45500-45512	3.3	3
102	Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. 2021 , 4, 17-43		15
101	Gene therapy and targeted toxins for glioma. 2011 , 11, 155-80		57
100	Prognostic Relevance of SFRP1 Gene Promoter Methylation in Colorectal Carcinoma. 2019 , 20, 1571-1577		8
99	Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification. 2015 , 3, 95		61
98	A Consideration of MGMT Gene Promoter Methylation Analysis for Glioblastoma Using Methylation-Specific Polymerase Chain Reaction and Pyrosequencing. 2011 , 45, 21		3
97	O-methylguanine-DNA methyltransferase promoter methylation and isocitrate dehydrogenase mutation as prognostic factors in a cohort of Saudi patients with glioblastoma. 2019 , 39, 410-416		3
96	Clinical Neuropathology Practice News 4-2012: levels of evidence for brain tumor biomarkers. 2012 , 31, 206-9		8
95	Clinical neuropathology practice guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers. 2013 , 32, 148-58		21
94	Molecular diagnostics of gliomas. 2011 , 135, 558-68		55
93	Central Nervous System Malignancies. 2021 , 731-754		
92	ATR inhibition reverses the resistance of homologous recombination deficient MGMT/MMR cancer cells to temozolomide. <i>Oncotarget</i> , 2021 , 12, 2114-2130	3.3	0
91	Genetic Polymorphisms in Pharmaceuticals and Chemotherapy. <i>World Journal of Oncology</i> , 2021 , 12, 149-154	16.7	1
90	High-Grade Astrocytomas. 2011 , 195-232		

- 89 Glioblastoma Patients: Role of Methylated MGMT. **2011**, 73-79
- 88 Gliomagenesis: Advantages and Limitations of Biomarkers. **2011**, 11-24 0
- 87 Current approaches to improve the anticancer chemotherapy with alkylating agents: state of the problem in world and Ukraine. *Biopolymers and Cell*, **2012**, 28, 83-92 0.3 3
- 86 Epigenomic and Noncoding RNA Regulation in Addictive Processes. *Epigenetics and Human Health*, **2013**, 115-165
- 85 TYPES OF DNA DAMAGE. **2013**, 115-118
- 84 [Modern molecular approaches to diagnosis and treatment of high-grade brain gliomas]. *Zhurnal Voprosy Neirokhirurgii Imeni N N Burdenko*, **2014**, 78, 85-100
- 83 Methylguanine-DNA methyltransferase (MGMT).
- 82 Cytotoxic Chemotherapy and Targeted Therapy for Aggressive Pituitary Tumors. **2017**, 581-594
- 81 Molecular Epidemiology of Diffuse Low-Grade Glioma. **2017**, 55-72
- 80 Molecular Testing for Glioblastoma. **2017**, 339-347
- 79 The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space. 1
- 78 Neuropathologie und Biomarker von Gliomen. **2018**, 3-28
- 77 CNS Tumors in Older Adults. **2018**, 1-9
- 76 Multiregional Radiomics Phenotypes at MR Imaging Predict MGMT Promoter Methylation in Glioblastoma. *IFMBE Proceedings*, **2019**, 143-146 0.2
- 75 The role of the deficient DNA mismatch repair system as a factor of sensitivity to targeted therapy for glioblastoma multiforme. *Onkologiya Zhurnal Imeni P A Gertsena*, **2019**, 8, 379 0.2
- 74 Pre-operative Overall Survival Time Prediction for Glioblastoma Patients Using Deep Learning on Both Imaging Phenotype and Genotype. *Lecture Notes in Computer Science*, **2019**, 11764, 415-422 0.9 4
- 73 Imaging Genomics. **2020**, 223-239
- 72 Comprehensive analysis of lncRNAs reveals candidate prognostic biomarkers in multiple cancer types.

71 CNS Tumors in Older Adults. **2020**, 813-821

70 Encyclopedia of Gerontology and Population Aging. **2020**, 1-8

69 Current Translational Insights into MGMT Methylation Regulating Temozolomide Sensitivity and Resistance in Glioblastoma Multiforme. *Current Pharmacogenomics and Personalized Medicine*, **2020**, 17, 76-93 0.4

68 BRCA1 identified as a modulator of temozolomide resistance in P53 wild-type GBM using a high-throughput shRNA-based synthetic lethality screening. *American Journal of Cancer Research*, **2019**, 9, 2428-2441 4.4 1

67 MiRNA-130a-3p inhibits cell proliferation, migration, and TMZ resistance in glioblastoma by targeting Sp1. *American Journal of Translational Research (discontinued)*, **2019**, 11, 7272-7285 3 8

66 Clinical and Prognostic Implications of 1p/19q, Promoter, and Promoter Alterations, and Expression of Ki-67 and p53 in Human Gliomas. *Cancer Management and Research*, **2021**, 13, 8755-8765 3.6 1

65 Encyclopedia of Gerontology and Population Aging. **2021**, 5208-5215

64 Extent of promoter methylation modifies the effect of temozolomide on overall survival in patients with glioblastoma: a regional cohort study.. *Neuro-Oncology Advances*, **2021**, 3, vdab171 0.9 1

63 Current insights on extracellular vesicle-mediated glioblastoma progression: Implications in drug resistance and epithelial-mesenchymal transition.. *Biochimica Et Biophysica Acta - General Subjects*, **2021**, 1866, 130065 4 1

62 Targeting Glioblastoma via Selective Alteration of Mitochondrial Redox State.. *Cancers*, **2022**, 14, 6.6 1

61 A Randomized Feasibility Study Evaluating Temozolomide Circadian Medicine in Patients with Glioma. 1

60 The effect of levetiracetam treatment on survival in patients with glioblastoma: a systematic review and meta-analysis.. *Journal of Neuro-Oncology*, **2022**, 156, 257 4.8 1

59 XAF1 directs glioma response to temozolomide through apoptotic transition of autophagy by activation of ATM-AMPK signaling.. *Neuro-Oncology Advances*, **2022**, 4, vdac013 0.9

58 Profiling Demethylase Activity Using Epigenetically Inactivated Dnazyme. *SSRN Electronic Journal*, 1

57 Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143.. *Neuro-Oncology Advances*, **2022**, 4, vdac025^{0.9} 2

56 Innovating Strategies and Tailored Approaches in Neuro-Oncology.. *Cancers*, **2022**, 14, 6.6

55 Recycling of SLC38A1 to the plasma membrane by DSCR3 promotes acquired temozolomide resistance in glioblastoma.. *Journal of Neuro-Oncology*, **2022**, 157, 15 4.8 0

54 Is There a Role for Epigenetic Therapies in Modulating DNA Damage Repair Pathways to Enhance Chemotherapy and Overcome Drug Resistance?. *Cancers*, **2022**, 14, 6.6 0

53	Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	2
52	MD2 Is a Potential Biomarker Associated with Immune Cell Infiltration in Gliomas.. <i>Frontiers in Oncology</i> , 2022 , 12, 854598	5.3	0
51	Glioblastoma in the Elderly: Review of Molecular and Therapeutic Aspects.. <i>Biomedicines</i> , 2022 , 10,	4.8	1
50	Genome-Wide Analysis for the Regulation of Gene Alternative Splicing by DNA Methylation Level in Glioma and its Prognostic Implications.. <i>Frontiers in Genetics</i> , 2022 , 13, 799913	4.5	
49	Neurosurgery's Impact on Neuro-Oncology: Can We Do Better? Lessons Learned Over 50 Years. <i>Neurosurgery</i> , 2022 , 68, 17-26	3.2	
48	Development and validation of a novel survival prediction model for newly diagnosed lower-grade gliomas.. <i>Neurosurgical Focus</i> , 2022 , 52, E13	4.2	0
47	LncRNA UCA1/miR-182-5p/MGMT axis modulates glioma cell sensitivity to TMZ through MGMT-related DNA damage pathways.. <i>Human Pathology</i> , 2022 ,	3.7	0
46	TMBIM1 promotes proliferation and attenuates apoptosis in glioblastoma cells by targeting the p38 MAPK signalling pathway.. <i>Translational Oncology</i> , 2022 , 19, 101391	4.9	0
45	Profiling demethylase activity using epigenetically inactivated DNase.. <i>Biosensors and Bioelectronics</i> , 2022 , 207, 114186	11.8	0
44	Detection of MGMT methylation status using a Lab-on-Chip compatible isothermal amplification method. <i>Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference</i> , 2021 , 2021, 7385-7389	0.9	
43	Targeting DNA repair pathway in cancer: Mechanisms and clinical application.. <i>MedComm</i> , 2021 , 2, 654-691	6.1	3
42	Tumors of the Glia: Recent Advances. 2022 , 353-386		
41	Clinical and radiographic characteristics of diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma: a single institution review.. <i>Journal of Neuro-Oncology</i> , 2022 ,	4.8	0
40	Valganciclovir as Add-on to Second-Line Therapy in Patients with Recurrent Glioblastoma.. <i>Cancers</i> , 2022 , 14,	6.6	0
39	Bioinformatics Analysis of Stem Cell circ-ASB3 Signaling Pathway and Its Affection on Glioma Biological Characteristics.. <i>Frontiers in Neuroinformatics</i> , 2022 , 16, 859937	3.9	
38	Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter: An International Randomized Phase 3 Trial.. <i>Neuro-Oncology</i> , 2022 ,	1	6
37	data_sheet_1.docx. 2018 ,		
36	Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients.. <i>Journal of Neuro-Oncology</i> , 2022 , 1	4.8	0

35	Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	
34	Glioblastom. <i>Tumor Diagnostik Und Therapie</i> , 2022 , 43, 239-245	0.1	
33	Phase 3 Trial of Chemoradiotherapy With Temozolomide Plus Nivolumab or Placebo for Newly Diagnosed Glioblastoma With Methylated MGMT Promoter.. <i>Neuro-Oncology</i> , 2022 ,	1	8
32	Clinical measures, radiomics, and genomics offer synergistic value in AI-based prediction of overall survival in patients with glioblastoma. <i>Scientific Reports</i> , 2022 , 12,	4.9	0
31	Targeting Glioblastoma Stem Cells to Overcome Chemoresistance: An Overview of Current Therapeutic Strategies. <i>Biomedicines</i> , 2022 , 10, 1308	4.8	1
30	Pharmacological targets for the induction of ferroptosis: Focus on Neuroblastoma and Glioblastoma. <i>Frontiers in Oncology</i> , 12,	5.3	0
29	Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients. <i>Pharmacological Research</i> , 2022 , 106290	10.2	0
28	Low-intensity ultrasound: A novel technique for adjuvant treatment of gliomas. <i>Biomedicine and Pharmacotherapy</i> , 2022 , 153, 113394	7.5	
27	Improving MGMT methylation status prediction of glioblastoma through optimizing radiomics features using genetic algorithm-based machine learning approach. 2022 , 12,		2
26	MGMT Promoter Methylation as a Prognostic Factor in Primary Glioblastoma: A Single-Institution Observational Study. 2022 , 10, 2030		2
25	Multi-plane UNet++ Ensemble for Glioblastoma Segmentation. 2022 , 285-294		0
24	The predictive value of partial MGMT promoter methylation for IDH-wildtype glioblastoma patients.		0
23	Bulk and Single-Cell Transcriptome Analyses Revealed That the Pyroptosis of Glioma-Associated Macrophages Participates in Tumor Progression and Immunosuppression. 2022 , 2022, 1-35		0
22	A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastoma.		0
21	A high-density 3-dimensional culture model of human glioblastoma for rapid screening of therapeutic resistance.		0
20	Outcome and characteristics of patients with adult grade 4 diffuse gliomas changing sites of treatment.		0
19	Beyond Imaging and Genetic Signature in Glioblastoma: Radiogenomic Holistic Approach in Neuro-Oncology. 2022 , 10, 3205		1
18	Quantitative analysis of MGMT promoter methylation status changes by pyrosequencing in recurrent glioblastoma.		0

17	Apparent Diffusion Coefficient as Imaging Biomarker for Identifying IDH Mutation, 1p19q Codeletion, and MGMT Promoter Methylation Status in Patients With Glioma.	1
16	Upstaging and Downstaging in Gliomas—Clinical Implications for the Fifth Edition of the World Health Organization Classification of Tumors of the Central Nervous System. 2023 , 13, 197	0
15	A high-density 3-dimensional culture model of human glioblastoma for rapid screening of therapeutic resistance. 2023 , 208, 115410	0
14	Nomogram Model for Predicting the Prognosis of High-Grade Glioma in Adults Receiving Standard Treatment: A Retrospective Cohort Study. 2023 , 12, 196	0
13	Epigenetically programmed resistance to chemo- and immuno-therapies. 2023 ,	0
12	Let's Get Physical: On Observing Force Perturbations of Proliferating Glioblastomal Cells.	0
11	Defining a Correlative Transcriptional Signature Associated with Bulk Histone H3 Acetylation Levels in Adult Glioblastomas. 2023 , 12, 374	0
10	Implantation of hydrogel-liposome nanoplatform inhibits glioblastoma relapse by inducing ferroptosis. 2023 , 100800	0
9	MRI-Based Deep Learning Tools for MGMT Promoter Methylation Detection: A Thorough Evaluation. 2023 , 15, 2253	0
8	Endocannabinoids are potential inhibitors of glioblastoma multiforme proliferation. 2023 , 21, 120-129	0
7	A Rare Triploid Involving the Coexistence of Glioblastoma Multiforme, Arteriovenous Malformation and Intracranial Aneurysm: Illustrative Case and Literature Review. 2023 , 59, 331	0
6	Assessment of Treatment Response to Dendritic Cell Vaccine in Patients with Glioblastoma using a Multiparametric MRI-Based Prediction Model	0
5	Peritumoral ADC Values Correlate with the MGMT Methylation Status in Patients with Glioblastoma. 2023 , 15, 1384	0
4	Exploring Novel Therapeutic Opportunities for Glioblastoma Using Patient-Derived Cell Cultures. 2023 , 15, 1562	0
3	Systematic in vitro analysis of therapy resistance in glioblastoma cell lines by integration of clonogenic survival data with multi-level molecular data. 2023 , 18,	0
2	RNA cytosine methyltransferase NSUN5 promotes protein synthesis and tumorigenic phenotypes in glioblastoma.	0
1	Brain Tumor Radiogenomic Classification of O6-Methylguanine-DNA Methyltransferase Promoter Methylation in Malignant Gliomas-Based Transfer Learning. 2023 , 30, 107327482311691	0